ARRY-OLD
ARRAY BIOPHARMA INC
ARRAY BIOPHARMA INC historical holders
total: 1
Fairfax Financial Holdings ARRAY BIOPHARMA INC transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2019 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2019 Q3
Prem Watsa has been an institutional investor in ARRAY BIOPHARMA INC (ARRY-OLD) since 2019 Q2. According to 2026 Q1 report, Prem Watsa doesn't hold any shares. The fund/company first acquired ARRY-OLD in 2019 Q2, initially purchasing 27,500 shares. Since the initial investment, Fairfax Financial Holdings has made 1 more transaction in this position.
When did Prem Watsa exit their ARRY-OLD position?
Prem Watsa no longer holds ARRAY BIOPHARMA INC (ARRY-OLD). They sold off their entire position in 2019 Q3, closing out an investment that began in 2019 Q2.
When did Prem Watsa first invest in ARRY-OLD?
Prem Watsa first invested in ARRAY BIOPHARMA INC (ARRY-OLD) in 2019 Q2 at the reported quarter-end price of $46.29 per share, acquiring 27,500 shares in their initial purchase.
What is Prem Watsa's average cost basis for ARRY-OLD?
Based on historical transaction data, Prem Watsa's estimated cost basis for ARRAY BIOPHARMA INC (ARRY-OLD) is approximately $46.29 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $46.29
- Weighted AVG sell price:
- $46.29
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.